The recent Consensus Statement on the diagnosis and management of prolactin-secreting pituitary adenomas (prolactinomas) drew attention to molecular pathogenetic mechanisms. We comment that somatic screening for SF3B1 hotspot variants in select cases might alert to aggressive tumour behaviour and prompt the timely management and intense follow up of these challenging tumours.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Petersenn, S. et al. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nat. Rev. Endocrinol. 19, 722–740 (2023).
Song, Z. J. et al. The genome-wide mutational landscape of pituitary adenomas. Cell Res. 26, 1255–1259 (2016).
Neou, M. et al. Pangenomic classification of pituitary neuroendocrine tumors. Cancer Cell 37, 123–134.e5 (2020).
Zhang, F. et al. Integrated proteogenomic characterization across major histological types of pituitary neuroendocrine tumors. Cell Res. 32, 1047–1067 (2022).
Li, C. et al. Somatic SF3B1 hotspot mutation in prolactinomas. Nat. Commun. 11, 2506 (2020).
Simon, J. et al. Prevalence and clinical correlations of SF3B1 variants in lactotroph tumours. Eur. J. Endocrinol. 189, 372–378 (2023).
Duhamel, C. et al. Immunotherapy in corticotroph and lactotroph aggressive tumors and carcinomas: two case reports and a review of the literature. J. Pers. Med. 10, 88 (2020).
Tang, H. et al. Case report: temozolomide treatment of refractory prolactinoma resistant to dopamine agonists. Front. Endocrinol. (Lausanne) 12, 616339 (2021).
Raverot, G. et al. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur. J. Endocrinol. 178, G1–G24 (2018).
Acknowledgements
M.T. acknowledges the support of the Deutsche Forschungsgemeinschaft (DFG) (grant number 314061271-TRR 205).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Theodoropoulou, M., Petersenn, S., Chanson, P. et al. Evidence for somatic mutation screening on aggressive prolactinomas. Nat Rev Endocrinol (2024). https://doi.org/10.1038/s41574-024-01010-x
Published:
DOI: https://doi.org/10.1038/s41574-024-01010-x
